Page last updated: 2024-11-08

agaritine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID439517
CHEBI ID15336
SCHEMBL ID2678851
MeSH IDM0065102

Synonyms (27)

Synonym
2-amino-5-{2-[4-(hydroxymethyl)phenyl]hydrazino}-5-oxopentanoic acid
brn 0757731
ccris 5459
nci-c08899
beta-n-(alpha-l-glutamyl)-4-hydroxymethylphenylhydrazine
hsdb 4202
l-glutamic acid, 5-(2-(alpha-hydroxy-para-tolyl)hydrazide)
beta-n-(gamma-l(+)glutamyl)4-hydroxymethylphenylhydrazine
glutamic acid, 5-(2-(alpha-hydroxy-p-tolyl)hydrazide), l-
agaritine ,
C01550
2757-90-6
l-glutamic acid, 5-(2-(4-(hydroxymethyl)phenyl)hydrazide)
(2s)-2-amino-5-{2-[4-(hydroxymethyl)phenyl]hydrazino}-5-oxopentanoic acid
2-[4-(hydroxymethyl)phenyl]-l-glutamohydrazide
beta-n-[gamma-l(+)-glutamyl]-4-hydroxymethylphenylhydrazine
CHEBI:15336
(2s)-2-amino-5-[2-[4-(hydroxymethyl)phenyl]hydrazinyl]-5-oxopentanoic acid
unii-ux8y7qvp8m
ux8y7qvp8m ,
agaritine [mi]
agaritine [iarc]
SCHEMBL2678851
DTXSID9020661
l-glutamic acid, 5-[2-[4-(hydroxymethyl)phenyl]hydrazide]
Q2315302
AKOS040750187
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
L-glutamic acid derivativeA proteinogenic amino acid derivative resulting from reaction of L-glutamic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of L-glutamic acid by a heteroatom.
benzyl alcoholsCompounds containing a phenylmethanol skeleton.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (27.03)18.7374
1990's10 (27.03)18.2507
2000's12 (32.43)29.6817
2010's5 (13.51)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]